Table 3.

Univariate analysis of relative risk of specific variables on outcome in gangliogliomas.

All adverse outcomes			High‐grade progression/death
Variable	RR (95% CI)	P	Variable	RR	P
IDH1‐mutant	1.38 (1.05–1.81)	0.0007	IDH1‐mutant	2.89 (0.93–8.96)	0.0002
WHO grade >I	1.47 (1.07–2.01)	0.0046	WHO grade >I	4.09 (0.71–23.7)	0.0074
Any mitoses	1.61 (0.92–2.01)	0.060	Age ≥20 years	∞	0.0055
Non‐temporal	1.37 (0.80–2.35)	0.31	Any mitoses	1.20 (0.93–1.55)	0.061
Male gender	1.17 (0.64–2.15)	0.62	Male gender	1.31 (0.41–4.18)	0.70
Age ≥20 years	1.07 (0.64–1.77)	1.00	Non‐temporal	1.10 (0.48–2.51)	1.00

Outcomes of 86 gangliogliomas were scored for either all adverse outcome or strictly for high‐grade progression/death (see Methods). Variables were ranked according to statistical significance of relative risk (RR; via Fisher's exact test) in correlating with each type of outcome. (∞ = no case under 20 years old showed high‐grade progression or death.) Of note, the World Health Organization (WHO) grade >I group includes all gangliogliomas with “atypical” features as well as grade III anaplastic gangliogliomas (Table 1).